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Abstract
Approximately 40% of patients who survive acute episodes of thrombotic thrombocytopenic
purpura (TTP) associated with severe acquired ADAMTS13 deficiency experience one or
more relapses. Risk factors for relapse other than severe ADAMTS13 deficiency and
ADAMTS13 autoantibodies are unknown. ADAMTS13 autoantibodies, TTP episodes fol-
lowing infection or type I interferon treatment and reported ensuing systemic lupus erythe-
matosus in some patients suggest immune dysregulation. This cross-sectional study asked
whether autoantibodies against RNA-binding proteins or peripheral blood gene expression
profiles measured during remission are associated with history of prior relapse in acquired
ADAMTS13-deficient TTP. Peripheral blood from 38 well-characterized patients with auto-
immune ADAMTS13-deficient TTP in remission was examined for autoantibodies and glob-
al gene expression. A subset of TTP patients (9 patients, 24%) exhibited a peripheral blood
gene signature composed of elevated ribosomal transcripts that associated with prior re-
lapse. A non-overlapping subset of TTP patients (9 patients, 24%) displayed a peripheral
blood type I interferon gene signature that associated with autoantibodies to RNA-binding
proteins but not with history of relapse. Patients who had relapsed bimodally expressed
higher HLA transcript levels independently of ribosomal transcripts. Presence of any one
potential risk factor (ribosomal gene signature, elevated HLA-DRB1, elevated HLA-DRB5)
associated with relapse (OR = 38.4; p = 0.0002) more closely than any factor alone or all
factors together. Levels of immune transcripts typical of natural killer (NK) and T
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lymphocytes positively correlated with ribosomal gene expression and number of prior epi-
sodes but not with time since the most recent episode. Flow cytometry confirmed elevated
expression of cell surface markers encoded by these transcripts on T and/or NK cell sub-
sets of patients who had relapsed. These data associate elevated ribosomal and immune
transcripts with relapse history in acquired, ADAMTS13-deficient TTP.
Introduction
Thrombotic thrombocytopenic purpura (TTP) associated with severe, acquired ADAMTS13
deficiency is an uncommon, acute episodic disorder with risk for relapse [1]. Persistence of se-
vere ADAMTS13 deficiency during clinical remission of some patients [1], and delayed occur-
rence of TTP until adulthood in other individuals with complete genetic deficiency of
ADAMTS13 activity [2] suggest that ADAMTS13 deficiency alone may be insufficient to initi-
ate acute clinical TTP episodes. Documentation of acute episodes of TTP following infection
[3], inflammation [4], and pharmacologic treatment with interferon-α, a type I interferon
(IFN) [5], suggests that inflammation is a possible trigger of acute episodes in this disorder.
Since the advent of plasma exchange to treat TTP, survival of the initial episode improved
from 20% to 70–79% [1,6]. Improved survival rates subsequently revealed potential for relapse
[7,8]. Reported risk factors for relapse susceptibility among idiopathic TTP patients include se-
vere deficiency of ADAMTS13 activity (<10%) at the time of an episode [1] or during remis-
sion [9]. However, only 40% of TTP patients with severely deficient ADAMTS13 will relapse
[1]. This observation and the absence of a clear relationship between ADAMTS13 levels during
remission and subsequent relapse [1] suggest a need for additional markers of relapse. Impor-
tantly, the biological basis of relapse in ADAMTS13-deficient TTP is unknown.
The discovery of ADAMTS13 antibody responses in patients with acquired TTP [10,11] posi-
tions this disease within the spectrum of autoimmune disorders. In a previous study of 31
ADAMTS13-deficient TTP patients, 9 had other autoimmune co-morbid conditions, including
non-destructive polyarthritis, Raynaud’s phenomenon, autoimmune endocrinopathies, discoid
lupus and systemic lupus erythematosus (SLE) [12]. TTP shares several characteristics with SLE,
including demographic population targeted [13] and flares or episodes separated by periods of
relative health. SLE can clinically appear as thrombotic microangiopathy and is a differential di-
agnosis for observation of thrombocytopenia and microangiopathic hemolytic anemia [14,15].
A review of case reports found 87 patients having clinical evidence for both TTP and SLE [13].
A close relationship was demonstrated between childhood-diagnosed idiopathic TTP and later
partial or complete SLE diagnosis [16]. More recently, we showed a great increase in the preva-
lence of SLE among TTP survivors [17]. In addition, anti-nuclear autoantibodies (ANA), typical
of though not specific for SLE, were detected in patients with acute and quiescent TTP [12,13].
Elevated type I IFN, promoted by immune complexes comprised of RNA-binding proteins,
including Ro, La, Smith (Sm) and/or Nuclear Ribonuclear Protein (nRNP) [18], bound to anti-
RNA-binding protein-specific autoantibodies, has emerged as a major driver of immune dysre-
gulation in SLE [19]. Such RNA-containing immune complexes activate plasmacytoid dendritic
cells to produce type I IFN by triggering RNA-binding Toll-like receptors following Fc recep-
tor-mediated uptake [20–22]. Stimulation of RNA-binding Toll-like receptors in plasmacytoid
dendritic cells normally promotes immune responses to viral pathogens. In SLE patients, how-
ever, elevated serum type I IFN activity and/or increased type I IFN-responsive gene expression
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associates with autoantibodies specific for RNA-binding proteins [23], elevated disease activity
[23–26], particular genetic polymorphisms [27] and major multi-organ involvement [28].
The discovery of ANAs in patients with ADAMTS13-deficient TTP [12], increased preva-
lence of SLE after survival of TTP [17] and case reports of TTP episodes following interferon-
therapy [5] prompted us to examine ADAMTS13-deficient TTP patients in remission for evi-
dence of underlying ANA-driven, type I IFN-mediated inflammation and further test for possi-
ble association with relapse. We report here that a subset of TTP patients have a type I IFN
peripheral blood gene signature that associates with autoantibodies to RNA-binding proteins.
However, these linked features did not associate with history of TTP relapse. In contrast, a ri-
bosomal gene signature (RGS) and select immune transcripts commonly expressed in T and
natural killer (NK) lymphocytes demonstrated significant association with history of relapse in
ADAMTS13-deficent TTP patients in remission.
Patients and Methods
Patient recruitment and blood sampling
Patients were recruited from the Oklahoma TTP Registry. TTP was defined clinically by the
presence of thrombocytopenia and microangiopathic hemolytic anemia without another ap-
parent etiology. In all patients, the diagnosis of TTP was supported by the presence of severe
ADAMTS 13 deficiency (activity<10%). In all patients the TTP was acquired, not hereditary,
documented by the presence of an inhibitor of ADAMTS13 activity, a presumed autoantibody,
and/or the recovery of ADAMTS13 activity during remission. A relapse is defined as the recur-
rence of an acute episode of TTP, manifested by thrombocytopenia and microangiopathic he-
molytic anemia with severe ADAMTS13 deficiency, occurring more than 30 days following
occurrence of a remission. All patients were required to be episode-free for at least 2 months
for inclusion in the study. The only exclusion criterion was previous diagnosis with a rheumatic
autoimmune disorder. Two patients (one SLE patient and one Sjögren’s syndrome patient)
were excluded. Within the Registry, 41 living patients met eligibility criteria. Blood samples
were collected from 38 (93%) of 41 eligible TTP subjects during disease remission in 2009 for
gene expression studies and antibody measurements. Of the 38 patients included in the study,
16 had a history of relapse. For flow cytometry studies only, blood was collected from a subset
of the same patients (n = 9 relapse, n = 13 non-relapse) in 2012. None of the subjects experi-
enced a relapse during the three year time period between blood draws. Patients received im-
munosuppressive therapy in addition to plasma exchange for their acute episodes. No long-
term immunosuppressive therapy to prevent relapse was used. This research was approved by
the University of Oklahoma Health Sciences Center and Oklahoma Medical Research Founda-
tion institutional review boards, ensuring compliance with the Helsinki Declaration of 1975, as
revised in 2008. All participants provided written informed consent.
RNA purification and microarray procedure
Blood was collected into PAXgene Blood RNA tubes (762165, Qiagen PreAnalytiX, Hombrech-
tikon, Switzerland) as described by the manufacturer and stored at -80°C until processing.
RNA was purified with the PAXGene Blood RNA Kit and protocol (762164, Qiagen PreAnaly-
tiX). α and β globin RNA was reduced using the GLOBINclear Human kit (AM1980, Ambion,
Austin, TX, USA). RNA quantity was measured with a Nanodrop1000 spectrophotometer, and
RNA yields were 1–9 μg of RNA from 2.5 mL of whole blood. RNA quality was evaluated with
an Agilent 2100 Bioanalyzer, and RNA Integrity Numbers were7.6. RNA was labeled using
the Illumina TotalPrep RNA Amplification Kit (IL1791, Ambion, Inc., Austin). cRNA was hy-
bridized to Illumina WG-6 version 3 Expression BeadChips (Illumina Inc, San Diego, CA).
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Chips were scanned using an Illumina iSCAN scanner (Illumina, San Diego, CA, USA). Gene
expression data were deposited in NCBI’s Gene Expression Omnibus [29] (GSE36418).
Microarray gene expression analysis
Hypervariably expressed genes were identified and normalized as described previously [30].
Hierarchical clustering and heatmaps were generated with Spotfire Decision Site 9 (TIBCO,
Palo Alto, CA, USA).
Differential gene expression was determined using a method that incorporates an internal-
standard based approach of normalization and an associative t-test to minimize false positive
determinations as previously described [31,32]. Genes exhibiting normalized expression values
20 times the standard deviation of the statistically defined background were considered ex-
pressed. Genes differentially expressed1.5 fold passed the standard t-test significance level of
p<0.05 and passed an associative t-test threshold to eliminate false positive determinations.
For meta-analysis of gene expression trends, 3,600 human 2-color microarrays were down-
loaded from NCBI’s GEO database [29] as described previously [33], and their expressions nor-
malized so direct comparisons could be made [34]. Pearson’s correlation coefficients were
calculated for every gene upregulated in relapse patients (as defined above) versus every other
gene upregulated in relapse patients (as defined above) using data from these 3,600 microarrays.
This analysis asks whether genes upregulated in the experiments presented herein are normally
correlated with each other in other, unrelated experiments found in the public database. Differ-
entially expressed genes above threshold were then clustered based on their Pearson’s R-values,
enabling identification of recurring expression patterns (genes with prior positive correlations,
in this case, the RGS) and deviations from prior expression trends (genes that may be anti-cor-
related, in this case, the ten gene immune subset discussed in the Results section).
Autoantibody detection
Individual ELISAs were performed to sensitively detect serum autoantibodies to the RNA-
binding proteins Ro, La, Sm and nRNP using a pre-determined threshold of positivity that was
based on a value of 3 standard deviations above the mean values of a set of healthy control sera
as previously described [35].
Epithelial cell reporter assay for serum type I IFN activity
Type I IFN activity was measured in sera as described [23]. Briefly, 50% dilutions of test sera
were incubated with the WISH epithelial cell line for six hours followed by quantification of
WISH cell expression of the IFN-regulated genesMX-1, IFIT-1 and PKR relative to GAPDH by
RT-PCR. Samples in which the sum of standard deviations above a previously established stan-
dard set of healthy control sera was>2 were considered positive.
ADAMTS13 activity
Serum ADAMTS13 activity was measured as previously described [1] using immunoblot to de-
tect degradation of plasma-derived von Willebrand factor (vWF) substrate [36,37] and fluores-
cence of FRET-vWF73 substrate [38,39].
Flow Cytometry
All samples were evaluated on the same day. Frozen PBMCs (5 × 105) were thawed, washed
twice with RPMI 1640 complete medium (RPMI 1640 supplemented with 10% fetal bovine
serum, 2mM L-glutamine and 50 international unit (IU)/ml penicillin/streptomycin at 2.5 ×
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105 cells/ml) with benzonase (25U/ml; Sigma) and subsequently stained with fluorescently la-
beled anti-human CD3 (clone HIT3a, PerCP-Cy5.5), CD56 (HCD56, APC-Cy7), CD52
(HI186, Pacific Blue), CD69 (FN50, PE-Cy5) and CD244 (Cl.7, FITC) monoclonal antibodies
(Biolegend or ExBIO Praha), as well as the eFluor506 fixable viability dye (Invitrogen). Data of
live-gated cells were collected using a FACS LSR II flow cytometer (Becton Dickinson) and an-
alyzed using Flow Jo software (TreeStar).
Statistical analysis for prevalence, associations and correlations
When evaluating categorical data associations, Fisher’s exact test was used. Odds ratios (OR)
and 95% confidence intervals (CI) were calculated using the maximum likelihood estimator
(MLE) where applicable. In the event of a zero cell within the contingency table, the OR and CI
were calculated using the modified median unbiased estimator (MMUE) and exact bootstrap
distribution, respectively, as described previously [40]. For continuous data, a Student’s t-test or
Kolmogorov-Smirnov test was used. Correlation analyses were conducted using the Spearman
test. The Mann-Whitney test was used to evaluate differences in cell surface marker expression
by flow cytometry. All tests were two-tailed. Statistical calculations were performed using SAS
(Version 9.2, SAS Institute, Cary, NC, USA), GraphPad Prism 6, or R (version 3.1.0).
Results
TTP patients in remission display ribosomal or type I IFN peripheral
blood gene signatures that associate with relapse or autoantibody
phenotypes
Relapse occurrence in only some ADAMTS13-deficient TTP patients [1] suggests the potential
for biologic heterogeneity in the TTP patient population that could contribute to relapse risk.
As a first step to identify transcriptional correlates of relapse, we elected to perform a cross-sec-
tional study of global gene expression in the peripheral blood of ADAMTS13-deficient TTP pa-
tients in remission. To avoid detection of inflammatory signatures that are a consequence of an
acute episode and associated tissue damage, all remission samples were collected after at least 2
months had elapsed since the most recent episode. Characteristics of the studied cohort of 38
patients at the time of sample collection are shown in Table 1. The median number of episodes
in the relapse group was 3 (range 2–5). No significant differences between the relapse and non-
relapse groups were detected in terms of age, race or sex. A slight difference in follow-up time
was noted between the two groups, with 9.8 (range 3.6–26.6) and 6.8 (range 0.8–12.8) median
years of follow-up for the relapse and non-relapse groups, respectively. Median times since the
most recent episode did not differ between the two groups.
RNA isolated from whole peripheral blood was evaluated for global gene expression. To investi-
gate heterogeneity of peripheral blood gene expression, hypervariably-expressed genes were identi-
fied, normalized and subjected to unsupervised hierarchical clustering. This analysis revealed two
predominant clusters (Fig. 1, S1–S2 Tables). The first cluster, comprised of 47 probes (42 unique
genes), contains elevated expression of 24 (57%) known type I IFN-regulated transcripts (S2 Table)
and was designated the type I IFN gene signature. From this signature, the average normalized ex-
pression of the known type I IFN-induced genes was calculated, and the nine individuals with an
average of1.0 were classified as having a type I IFN gene signature (Fig. 1, bottom arrowheads).
Hierarchical clustering of hypervariable genes revealed a second cluster of 73 probes
(57 unique transcripts; 5 putative transcripts were discontinued in the current genome assembly
and therefore excluded) that encodes primarily (75%) structural ribosomal proteins or other
translation machinery components. This cluster, termed the ribosomal gene signature (RGS, S1
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Table), also contains genes encoding products involved in energy production and proliferation
(11%), including the immune cell activation marker CD69. The nine individuals with an average
normalized expression of the 73 probes of1.0 were classified as having a ribosomal gene signa-
ture (Fig. 1, top arrowheads). Thus, both type I IFN and ribosomal peripheral blood gene expres-
sion signatures were identified within a group of 38 ADAMTS13-deficient TTP patients during
remission, and presence of these signatures was heterogeneous within the patient population.
Increased type I IFN gene signatures and enhanced type I IFN activity have been associated
with autoantibodies specific for RNA-binding proteins in the autoimmune disease SLE [23].
To determine if a similar association is present in ADAMTS13-deficient TTP patients without
any known overlapping rheumatic diseases, the patient serum samples were tested for autoanti-
bodies to the Ro, La, Sm and nRNP RNA-binding proteins using antigen-specific ELISAs and
the data compared with presence of the type 1 IFN gene signature. Of the 38 patients tested, 12
had detectable antibodies to one or more of these RNA binding antigens, with the following
pattern of reactivity: Ro only = 7 patients, Ro and nRNP = 2 patients, nRNP only = 1 patient,
Sm and nRNP = 1 patient, La only = 1 patient. Positivity for the type I IFN signature associated
with presence of elevated serum type I IFN activity, with 4 of 9 (44%) IFN signature positive
patients having high type 1 IFN activity and 2 of 29 (7%) IFN signature negative patients hav-
ing high type 1 IFN activity (p = 0.020; OR = 9.85, 95%CI 1.09–137.4, S1 Fig.). Positivity for
the IFN signature also associated with presence of autoantibodies specific for RNA-binding
proteins, with 6 of 9 (66%) IFN signature positive patients and 6 of 29 (10%) IFN signature
negative patients producing the antibodies (p = 0.016; OR = 7.16, 95% CI 1.14–58.23; Fig. 2A
left). Notably, however, the type I IFN signature did not associate with history of relapse
(p = 0.706; OR = 0.62, 95% CI 0.08–3.64; Fig. 2A right).
The patient data were then analyzed to determine whether the RGS associates with presence
of autoantibodies to RNA-binding proteins or relapse history. While no association was de-
tected between the RGS and autoantibodies to RNA-binding proteins (p = 0.223; OR = 0.21,
95%CI 0.004–1.97; Fig. 2B), the RGS significantly associated with relapse history, as the pro-
portion of ribosomal gene signature-positive patients who had experienced one or more re-
lapses (7 of 9, 78%) is significantly higher than the proportion of ribosomal gene signature-
Table 1. Characteristics of TTP remission cohorta.
Relapse (n = 16) Non-Relapse (n = 22) p-value
Age ± SD 43.9 ± 15.9 45.3 ± 12.8 0.362b
Race/Ethnicity % [number] 0.199c
Caucasian 43.8% [7] 72.7% [16]
African American 43.8% [7] 22.7% [5]
American Indian 0.06% [1] 0.05% [1]
Hispanic 0.06% [1] 0% [0]
Sex % [number]
Female 68.8% [11] 95.5% [21] 0.065c
Median years follow-up [range] 9.8 [3.6–26.6] 6.8 [0.8–12.8] 0.0325d
Median years since last episode [range] 3.4 [0.2–13.2] 6.8 [0.8–12.8] 0.076d
a Individuals with a history of clinically diagnosed TTP (<10% ADAMTS13 activity during a prior acute
episode), in remission for at least 2 months, who fail to meet criteria for any known rheumatic disease;
b t-test;
c Fisher’s exact test;
d Kolmogorov-Smirnov test.
doi:10.1371/journal.pone.0117614.t001
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Fig 1. Heatmap of gene signatures present in peripheral blood of ADAMTS13-deficient TTP patients in remission. Transformed expression levels of
hypervariably expressed genes from the peripheral blood of ADAMTS13-deficient TTP patients were subjected to unsupervised clustering, revealing two
predominant gene signatures. Arrowheads above the charts indicate samples that were classified as positive for a ribosomal gene signature, and
arrowheads below the charts indicate samples that were classified as positive for a type I IFN gene signature. Asterisks indicate patients who had
experienced at least one relapse. Data were transformed to the same scale ranges, making average expression over samples of zero and standard deviation
of 1.0 for each gene. Colors indicate increased expression (red) or decreased expression (green).
doi:10.1371/journal.pone.0117614.g001
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negative patients who had experienced one or more relapses (9 of 29, 31%; p = 0.021, OR =
7.33, 95% CI 1.11–86.14; Fig. 2B). Moreover, the average ± SEM of normalized levels of ribo-
somal gene expression in relapse patients (0.729±0.267) is higher than that of non-relapse pa-
tients (-0.162±0.158, p = 0.0040, Fig. 3A).
TTP patients with a history of relapse differentially express ribosomal
and immune genes
To identify relapse-associated transcripts in ADAMTS13-deficient TTP more precisely, genes
differentially expressed between patients with or without a history of relapse were determined.
Within the relapse group, 98 probes detected 81 unique downregulated genes (ranging from 1.5
to 1.83 fold downregulation), while 142 probes detected 121 unique upregulated genes (ranging
from 1.5 to 13 fold upregulation, Fig. 3B, S3 and S4 Tables). Over 46% of transcripts downregu-
lated in relapse patients are expressed in neutrophils, including IL-8, CXCR1, FCGR2A, VNN3,
VNN2, NCF1B, FPR2, NCF1 (S3 Table). Despite this observation, complete blood cell counts re-
vealed that all peripheral blood cell subsets, including granulocytes, were within normal limits,
with no detectable differences between the relapse and non-relapse groups (S2 Fig.).
As expected, a large proportion (61%) of genes upregulated in the relapse group encode struc-
tural ribosomal proteins, components of translation machinery and protein products involved in
energy metabolism, thus confirming the association of a ribosomal gene signature with relapse
(S4 Table). Several transcripts encoding proteins functioning in the immune system were overex-
pressed in the relapse group, includingHLA-DRB1 (2.0 fold),HLA-DRB5 (3.4 fold), IFNG
(2.3 fold), CD69 (1.7 fold), GZMA (1.7 fold), P2RY5 (1.6 fold), KLRB1/CD161 (1.6 fold), CD244
(1.6 fold), CD52 (1.6 fold),MAF (1.6 fold) andHOPX (1.6 fold). A meta-analysis of expression of
the upregulated genes using publically available data from 3,600 other human microarray experi-
ments revealed that the expression levels of ribosomal genes generally correlate with one another
in settings other than TTP (S3 Fig.). Specifically, a total of 63 relapse-upregulated genes mapped
to probes within these arrays, and 69% (2,727/3,969) of the Pearson’s correlations were signifi-
cant at p<0.01. Expression levels of 10 of the 11 relapse-elevated immune transcripts (except
CD69) also correlated with one another in other experiments. Interestingly, however, expression
of these ten immune genes is ordinarily anti-correlated with that of the ribosomal genes. That is,
they tend not to be upregulated together with ribosomal genes in the other experiments analyzed,
as they were in relapsing TTP patients, suggesting their aberrant regulation in TTP.
Within these ten immune genes,HLA-DRB1 andHLA-DRB5 expression was bimodal, with
average ± SEM inDRB1 high (n = 23) and low (n = 15) groups equal to 740.6±48.6 and 38.1
±13.5, respectively, and average ± SEM inDRB5 high (n = 17) and low (n = 21) groups equal to
1007.0±63.0 and 4.2±0.8, respectively. High expression of these HLA-DR genes associated with
relapse (OR = 4.97, p = 0.043 for DRB1 and OR = 9.45, p = 0.003 for DRB5; Fig. 4A and
Table 2). Notably, all individuals with high expression ofDRB5 also exhibited high expression of
DRB1. High expression of these human leukocyte antigen (HLA) genes was not associated with
presence of the ribosomal gene signature (S4 Fig.), indicating that association ofHLA-DRB1
and-DRB5 expression with relapse is ribosomal gene signature-independent. Since the RGS and
high expression of DRB1 andDRB5 independently associated with relapse, we asked whether
presence of a combination of these factors would more strongly associate with relapse. Presence
of all three factors was significantly associated with relapse (Table 2). However, the presence of
any one of the factors was more strongly associated with relapse (OR = 38.5, p = .002 for “RGS+
or DRB1hi or DRB5hi”, Table 2) than having all of the factors together or any one factor alone.
In contrast toHLA-DRB1 and-DRB5 transcripts, expression of IFNG (r = 0.7875), GZMA
(r = 0.7938), P2RY5 (r = 0.9115), KLRB1/CD161 (0.7974), CD244 (r = 0.5875), CD52 (r =
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0.9452) andHOPX (r = 0.5871) (but notMAF) demonstrated significantly high positive correla-
tion with average ribosomal gene expression (Fig. 4B). CD69 also positively correlated with aver-
age ribosomal gene expression (r = 0.9048, S5 Fig.). Although no correlation was observed
between plasma ADAMTS13 activity levels in these remission samples and the number of acute
TTP episodes a patient had previously experienced, positive correlations were found between ex-
pression of five of the immune genes (KLRB1/CD161 (r = 0.3541), CD244 (r = 0.4909), CD52 (r
= 0.3538),MAF (r = 0.4904),HOPX (r = 0.3525) and number of episodes (Fig. 5). Furthermore,
neither levels of the ten immune transcripts nor average ribosomal gene expression nor plasma
ADAMTS13 activity levels were correlated with time elapsed since the most recent episode (S6
Fig.), indicating that gene expression levels of these transcriptional correlates of relapse are un-
likely to reflect inflammation caused by the most recent prior acute episode.
Plasma ADAMTS13 activity levels in the remission samples exhibited modest negative cor-
relations with transcript levels ofMAF (r = -0.372 [95% CI-0.624 to-0.050], p = 0.021) and
HOPX (r = -0.367 [95% CI-0.621 to-0.044], p = 0.023), genes that are both expressed in T help-
er cells (S5 Table). No correlation of remission ADAMTS13 activity levels were observed with
transcript levels of IFNG, GZMA, P2RY5, KLRB1/CD161, CD244 or CD52, or with averaged
Fig 2. Type I IFN and ribosomal gene expression signature associations. (A) Association of the type I
IFN gene signature with antibodies to RNA binding proteins (RBP) but not relapse history. (B) Association of
the ribosomal gene signature (RGS) with relapse history but not antibodies to RBP. Proportions were
compared using Fisher’s exact test. Odds ratios (OR) were calculated as described in Materials and
Methods.
doi:10.1371/journal.pone.0117614.g002
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Fig 3. Direct comparison of gene expression of peripheral blood samples between patients with or
without a history of relapse. (A) Average normalized ribosomal gene signature expression values in
patients with or without a history of relapse. Error bars depict standard error of the mean. Expression values
were compared using Student’s t-test. (B) Relative expression levels of genes differentially expressed
between relapse and non-relapse patients presented following clustering. Colors indicate relative increased
(red) or decreased (green) expression.
doi:10.1371/journal.pone.0117614.g003
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Fig 4. Relationship of relapse-over-expressed immune genes to the ribosomal gene signature. (A)
Association of increased HLA-DRB1 andHLA-DRB5 expression with history of relapse. Proportions were
compared using Fisher’s exact test. Y-axes are in normalized units. Expression levels>400 normalized units
were considered high. (B) Positive correlation of the patient ribosomal gene signature with expression of
seven of eight immune genes over-expressed in relapse patients. Spearman r values are shown. Y-axes are
in normalized units.
doi:10.1371/journal.pone.0117614.g004
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normalized values of ribosomal gene expression (S5 Table). No association of remission
ADAMTS13 activity levels with relapse status, high DRB1 expression, high DRB5 expression,
presence of RGS or presence of IFN gene signatures was observed (S6 Table).
Altered expression of cell surface markers on NK and T lymphocytes in
TTP patients with a history of relapse
Of the relapse-overexpressed immune transcripts, at least nine are known to be expressed in
NK or T lymphocytes. To investigate whether proteins encoded by these transcripts are elevat-
ed at the protein level, cell surface expression levels of CD52, CD161 and CD244, were mea-
sured on the major cytolytic (CD3-CD56dim) and minor regulatory (CD3-CD56bright) NK cell
subsets detectable in human blood [41] and on CD3+ T lymphocytes from 22 of the patients
(n = 9 relapse and n = 13 non-relapse). Compared to those from patients who had experienced
only a single acute episode, CD56dim but not CD56bright NK cells from patients who had re-
lapsed displayed elevated cell surface expression of CD52 (relapse: 191±10, non-relapse: 144±9
mean fluorescence intensity units ± SEM), CD161 (relapse: 6329±529, non-relapse: 3475±467)
and CD244 (relapse: 899±79, non-relapse: 630±46) (Fig. 6). CD3+ T lymphocytes from re-
lapsed patients expressed higher levels of CD52 (320±19) and CD161 (3937±590) compared to
those from non-relapse patients (251±41 and 2241±755 for CD52 and CD161, respectively),
while CD244 expression on T cells was not different between the two groups (Fig. 6). Thus,
ADAMTS13-deficient TTP patients in remission who had a history of relapse displayed altered
cell surface marker expression on peripheral blood NK and T lymphocytes.
Discussion
ADAMTS13 activity and/or autoantibody levels measured during acute TTP or remission have
been identified as risk factors for relapse [1,9]. However, observation of relapse in only a frac-
tion of patients exhibiting these markers highlights both an incomplete biologic understanding
of relapse and a need for additional markers. In this study we asked whether autoantibody-
related type I IFN inflammation is a feature of ADAMTS13-deficient TTP and, if so, whether
this inflammation is associated with relapse in this disorder. The results show that type I IFN-
mediated inflammation does indeed occur in TTP but does not associate with relapse history.
Therefore, we conclude that underlying elevations in type I IFN associated with the formation
of RNA-containing immune complexes do not promote relapse in TTP. However, the TTP pa-
tients exhibiting a type I IFN gene signature and autoantibodies directed to RNA binding pro-
teins might be at increased risk for developing SLE. All patients in this study fulfill the
Table 2. Association of RGS, HLA DR gene expression or combination thereof with relapse in
ADAMTS13-deﬁcient TTP.
Model OR a Lower 95% CI Upper 95% CI p-Value c
RGS+ 7.78 1.53 59.71 0.021
DRB1hi 4.97 0.97 34.97 0.043
DRB5hi 9.45 1.86 61.15 0.003
RGS+ & DRB1hi & DRB5hi 21.08 a 2.05 b 43.84 b 0.025
RGS+ or DRB1hi or DRB5hi 38.35 a 4.98 b 85.22 b 0.002
a Odds ratios (OR) estimated by modiﬁed median unbiased estimation (MMUE) due to zero cells;
b Conﬁdence intervals (CI) estimated by exact, bootstrapped MMUE;
c Fisher’s exact test, 2-tailed.
doi:10.1371/journal.pone.0117614.t002
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Hematologic Disorder SLE criterion [14,15], and 42% are positive for ANA, another SLE crite-
rion. A type I IFN gene signature has been described in patients with incomplete lupus [42],
and a pediatric study suggests that severely reduced ADAMTS13 activity in TTP patients
might portend the onset of SLE [16].
Evaluation of hypervariable gene expression in the TTP patient group revealed a ribosomal
gene signature that was significantly more common in patients with a history of relapse. Pat-
terns of global gene expression have proven useful for predicting prognosis and flares in anti-
neutrophil cytoplasmic antibody-associated vasculitis and SLE [43] and have been extensively
used to uncover disease-promoting biologic pathways in a variety of clinical settings. Although
no conclusions can be drawn from the present cross-sectional study regarding whether this
gene expression profile elevates risk for relapse in TTP, this finding suggests that a prospective
study to evaluate this question is warranted. Elevated ribosomal transcripts may suggest MYC-
dependent cell growth and proliferation [44,45]. Enhanced expression of translation machinery
could alternatively reflect enhanced differentiation of cell types producing large quantities of
protein, such as blood cells with high granule content.
To further evaluate the association of a ribosomal gene signature with relapse in TTP, we
also performed a direct comparison of differential global gene expression between the relapsed
patient group compared to the non-relapsed patient group. This analysis confirmed higher ex-
pression of multiple ribosomal and translational genes in relapsers and further pinpointed un-
usual co-elevated expression of several transcripts typically expressed in T and NK subsets of
lymphocytes, as well as increased expression of HLA class II genes in relapsed patients. The
Fig 5. Relationship between peripheral bloodmarkers and number of episodes. Expression of five
immune transcripts overexpressed in patients with history of relapse correlates with number of past TTP
episodes. Serum ADAMTS13 activity does not correlate with number of past episodes (upper left panel). Y-
axis is percent of full activity for ADAMTS13 as measured by FRET assay (upper left panel). Y-axis is gene
expression in normalized units for the five immune genes (all other panels). Spearman R values are shown.
doi:10.1371/journal.pone.0117614.g005
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bimodal, elevated expression of HLA-DRB1 andHLA-DRB5 in patients with a history of re-
lapse may signal association of a specific HLA haplotype with relapse in ADAMTS13-deficient
TTP. Elevated expression of the same HLA-DRB1 and -DRB5 probes from the same platform
utilized in the present study reflected presence of a specific HLA haplotype in a study of multi-
ple sclerosis [46]. Although selected HLA-DR and-DQ alleles have been reported to associate
with TTP [47,48], there are no reports of selected HLA alleles associating with relapse. This is
an important area for further investigation, as select HLA haplotypes may pre-dispose to
chronically increased ADAMTS13 autoantibodies.
Correlation of ribosomal gene expression with transcripts typically expressed in NK cells
(KLRB1/CD161, CD244, GZMA, IFNG) [41,49–51] and certain subsets of T-lymphocytes
(MAF,HOPX, GZMA, IFNG, CD52, KLRB1/CD161) [51–57] is consistent with activation and
proliferation of one or more subsets of these cells in TTP patients with a history of relapse. Sig-
nificant negative correlations between remission plasma levels of ADAMTS13 and transcripts
encoding the T helper cell transcriptional regulators Hopx [52] and Maf [57] suggest that pe-
ripheral blood T helper cells could promote relapse by chronically driving ADAMTS13
Fig 6. Expression of CD52, CD244 and CD161 protein on the cell surface of CD3-CD56dim NK and CD3+ T cells isolated from relapsed ADAMTS13-
deficient TTP patients in remission.Mean fluorescence intensity (MFI) of CD52, CD244 and CD161 on CD3-CD56dim and CD3-CD56bright NK cells (A) and
on CD3+ T cells (B) derived from relapsed (R) or non-relapsed (NR) TTP patients. Representative histograms of fluorescence intensity of markers exhibiting
significant differences between relapse (thick, dashed lines) and non-relapsed (thin, solid lines) patients are shown in C. (relapse n = 9, non-relapse n = 13,
Mann-Whitney test; **p<0.01).
doi:10.1371/journal.pone.0117614.g006
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autoantibodies in some patients. The involvement of T and/or NK lymphocytes is further sup-
ported by increased cell surface expression CD161, CD244 and CD52 on the CD3+CD56dim cy-
tolytic subset of NK cells and increased expression of CD161 and CD52 on CD3+ T cells from
patients who had experienced relapse. Importantly, lack of correlation of the ribosomal and im-
mune transcriptional signatures with time since the most recent episode suggests that the ob-
served transcriptional changes are not simply the result of lingering inflammation from the
most recent episode. However, there are multiple potential confounders for the analysis of the
outcome of relapse, such as recent rituximab treatment, pregnancy, surgical procedures, and
other events that may decrease or increase the risk for relapse in patients with acquired, auto-
immune TTP. Prospective studies combing gene expression profiling and immunophenotyp-
ing are required to determine whether the relapse-associated transcriptional signatures and
altered expression of NK and T lymphocyte cell surface markers reported here signify risk or
consequence of relapse in ADAMTS13-deficient TTP, and we have initiated collection of sam-
ples from newly diagnosed, ADAMTS13-deficient TTP patients for this purpose.
Possible explanations underlying these observations include ADAMTS13-independent ge-
netic variation that increases relapse risk or some form of immunologic memory or epigenetic
imprint left on T and NK lymphocytes by acute TTP episodes or other unknown environmen-
tal exposures. Interestingly, NK cells [58] and cytotoxic T lymphocytes [59], as well as GZMA
[60] and IFN- [61], two of their common products, can all cause endothelial damage, which
has been suggested to be a likely inciting event for TTP [62]. We speculate that microthrom-
bus-supporting endothelial damage in TTP could be promoted by ADAMTS13 autoantibody-
dependent cellular cytotoxicity, in which ADAMT13 autoantibodies bound to ADAMTS13 at
the endothelial surface [63] are engaged by Fc receptors on cytotoxic NK cells or cytotoxic T
lymphocytes. In addition to being a mediator of cytotoxicity, Granzyme A has also been shown
to stimulate pro-inflammatory IL-1, TNF and IL-6, secretion from macropahges [64]. Elevated
levels of these cytokines have been observed in acute TTP [65], and acute TTP plasma has been
shown to activate macrophages [66].
This study identifies an RBP autoantibody-associated type I IFN gene expression signature
in a subset of TTP patients in remission that does not associate with relapse. Moreover, this
cross-sectional study further reports a peripheral blood RGS, elevated expression of HLA-
DRB1 and-DRB5 transcripts, and elevated expression of a discrete set of NK and T lymphocyte
expressed immune genes as the first transcriptional correlates of relapse in ADAMTS13-defi-
cient TTP. These markers warrant further investigation as potential predictors of relapse in
this rare but deadly disorder.
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